• Opinion
• [Reporter's View] Switching of drugs reimbursable
• by Eo, Yun-Ho Jan 6, 2025 05:57am

• Policy
• Zolgensma shows 94% effect during post-evaluations
• by Lee, Tak-Sun Jan 6, 2025 05:56am

• Company
• 1st RSV preventive inj 'Beyfortus' can be prescribed
• by Eo, Yun-Ho Jan 6, 2025 05:56am

• Company
• Balversa may be prescribed at general hospitals in Korea
• by Eo, Yun-Ho Jan 6, 2025 05:56am

• Policy
• MFDS’s 2nd GIFT drug Nefecon applies for reimbursement
• by Lee, Tak-Sun Jan 6, 2025 05:56am

• Company
• Lily's 'Jaypirca' launches in KOR
• by Whang, byung-woo Jan 3, 2025 06:28am

• Company
• Will Fabhalta settle as a PNH treatment option in Korea?
• by Eo, Yun-Ho Jan 3, 2025 06:27am

• Policy
• 'Pivlaz Inj' makes another attempt to be reimb in KOR
• by Lee, Tak-Sun Jan 3, 2025 06:27am

• Policy
• New Year's drug pricing policy highlights
• by Lee, Tak-Sun Jan 3, 2025 06:27am

• Policy
• Prices for Vyndamax, Ocrevus in negotiations with NHIS
• by Lee, Tak-Sun Jan 3, 2025 06:27am